Publication:


abstract

BACKGROUND:

We tested the hypothesis that chronic treatment with sildenafil attenuates left ventricular (LV) remodeling and prevents exercise intolerance in chronic mitral regurgitation (MR).

METHODS AND RESULTS:

MR was created in Sprague-Dawley rats by making a hole on the mitral leaflet. Two weeks after MR creation, MR and LV dilatation were confirmed by echocardiography, and rats were randomly assigned to sildenafil treatment (MR+sildenafil group; 50 mg/kg PO twice a day; n=16) or normal saline only (MR group; n=16) and continued for 4 months. Sixteen sham rats were compared with MR rats. After 4 months, LV size was smaller in the MR+sildenafil compared with the MR group (LV end-systolic dimension, 4.7±0.3 for sham versus 5.9±0.3 for MR+sildenafil versus 7.4±0.5 mm for MR; P<0.05; LV end-diastolic dimension, 8.3±0.4 versus 10.5±0.2 versus 11.7±0.61 mm, respectively; P<0.05). LV ejection fraction was greater in the MR+sildenafil group than in the MR group (70.2±2.2 for sham versus 67.0±4.2 for MR+sildenafil versus 58.9±2.5 for MR; P=0.01). Serial treadmill test revealed that exercise capacity was reduced in the MR but not in the MR+sildenafil group. Transcriptional profiling of cardiac apical tissues revealed that gene sets related to inflammatory response, DNA damage response, cell cycle checkpoint, and cellular signaling pathways were significantly enriched by genes with reciprocal changes. Pathological analysis showed that perivascular fibrosis was more prominent in the MR than in the MR+sildenafil group and that the percentage of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling-positive cells was 2-fold greater in the MR compared with the MR+sildenafil group.

CONCLUSIONS:

Sildenafil significantly attenuates LV remodeling and prevents exercise intolerance in a rat model of chronic MR. This benefit may be associated with the antiapoptotic, anti-inflammatory effects of sildenafil.

Related Articles
Impact of mitral regurgitation on left ventricular anatomic and molecular remodeling and systolic function: implication for outcome.
Am J Physiol Heart Circ Physio...
Impact of mitral regurgitation on left ventricular anatomic and molecular remodeling and systolic function: implication for outcome.
Pu M, Gao Z, Zhang X, Liao D, Pu DK, Brennan T, Davidson WR Jr. Am J Physiol Heart Circ Physiol. 2009 Jun; 296(6):H1727-32. Epub 2009 Mar 27.
Is inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure?
Circulation. 2012
Is inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure?
Dai W, Kloner RA. Circulation. 2012 Mar 20; 125(11):1341-3. Epub 2012 Feb 8.
PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
Circ Heart Fail. 2011
PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
Guazzi M, Vicenzi M, Arena R, Guazzi MD. Circ Heart Fail. 2011 Jan; 4(1):8-17. Epub 2010 Oct 29.
Survival, exercise capacity, and left ventricular remodeling in a rat model of chronic mitral regurgitation: serial echocardiography and pressure-volume analysis.
Korean Circ J. 2011
Survival, exercise capacity, and left ventricular remodeling in a rat model of chronic mitral regurgitation: serial echocardiography and pressure-volume analysis.
Kim KH, Kim YJ, Lee SP, Kim HK, Seo JW, Sohn DW, Oh BH, Park YB. Korean Circ J. 2011 Oct; 41(10):603-11. Epub 2011 Oct 31.
Review Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: continued LV remodeling as a moving target.
Circulation. 2004
Review Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: continued LV remodeling as a moving target.
Hung J, Papakostas L, Tahta SA, Hardy BG, Bollen BA, Duran CM, Levine RA. Circulation. 2004 Sep 14; 110(11 Suppl 1):II85-90.